Abstract
Although there are experimental reports of cytochrome P450 3A4 iso-enzyme (CYP3A4) induction by glucocorticoids, there are no clinical reports about an interaction between tacrolimus and steroids. Therefore, tacrolimus trough level and dose were compared after dose-normalization before and after withdrawal of prednisolone. After withdrawal of 5 mg prednisolone, the median tacrolimus dose-normalized level increased by 14% in the retrospective (n=54), and by 11% in the prospective (n=8) part of the study. After withdrawal of 10 mg, this increase was 33% (n=30) and 36% (n=14), respectively. An additional pharmacokinetic part of the study (n=8) revealed an 18% increase in AUC (P=0.05) after withdrawal of 5 mg prednisolone, which is compatible with a reduced metabolism after steroid withdrawal. The significant increase in tacrolimus exposure after steroid withdrawal may on the one hand counteract the reduction in immunosuppression intended by steroid withdrawal, and, on the other hand, may result in an increase of serum creatinine which could be misinterpreted as rejection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boots JMM, van Duijnhoven EM, Christiaans MHL, Wolffenbuttel BHR, van Hooff JP (2002) Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. JASN 13: 221–227
Boots JMM, van Duijnhoven EM, Christiaans MHL, Nieman FHM, van Suylen RJ, van Hooff JP (2001) Single center experience with tacrolimus versus cyclosporin-Neoral in renal transplant recipients. Transpl Int 14: 370–383
Chakrabarti P, Wong HY, Scantlebury VP, Jordan ML, Vivas C, Ellis D, Lombardozzi-Lane S, Hakala TR, Fung JJ, Simmons RL, Strazl TE, Shapiro R (2000) Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus based immunosuppression. Transplantation 70: 760–764
Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schäfer A, van Hooff J (1998) Effects of breakfast on the oral bioavailibility of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 30: 1271–1273
Hricik DE, Kupin WL, First MR (1994) Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol [Suppl] 4: 10–16
Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE (2000) Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69: 834–841
Lo A, Burckart GJ (1999) P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 39: 995–1005
Mayer AD, Dmitrewski J, Squifflet JP, Bessen T, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RWG, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JLR, Talbot D, Neumayer HH, Hauser I, Ericzon BG, Brattström C, Claesson K, Mühlbacher F, Pohanka E (1997) Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64: 436–443
Moochhala SM, Lee EJD, Earnest L, Wong JYY, Ngoi SS (1991) Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. Transplant Proc 23: 2786–2788
Omar G, Shah LA, Thomson AW, Whiting PH, Burke MD (1993) FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc 23: 690–698
Oppenheimer F (2000) Steroid withdrawal in renal transplant recipients. Transplant Proc 32: 14–15
Piekoszewski W, Chow FS, Jusko WJ (1994) Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. Pharmacol Exp Ther 269: 103–109
Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS (1997) A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977–983
Plosker GL (2000) Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59: 323–389
Sattler M, Guengerich PF, Yun CH, Christians U, Sewing KF (1992) Cytochrome p-450 3A enzymes are responsible for biotransfromation of FK 506 and rapamycin in man and rat. Drug Metab Dispos 20: 753–761
Schulak JA, Hricik DE (1994) Steroid withdrawal after renal transplantation. Clin Transplant 8: 211–216
Sewing KF (1994) Pharmacokinetics, dosing principles and blood level monitoring of FK506. Transplant Proc 26: 3267–3269
Shah LA, Whiting PH, Omar G, Thomson AW, Burke MD (1991) Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant Proc 23: 2783–2785
Shapiro R, Jordan ML, Scantlebury VP (1995) The superiority of tacrolimus in renal transplant recipients the Pittsburgh experience. Clin Transpl 199–205
Tredger JM, Gilkes CD, Gonde CE (1999) Performance of the Imx tacrolimus II assay and practical limits of detection. Clin Chem 45: 1881–1882
Wallemacq PE, Leal T, Besse T, Squifflet J-P, Reding R, Otte J-B, Lerut J, Hassoun A (1997) Imx Tacrolimus II vs Imx tacrolimus microparticle enzyme immunoassay evaluated in renal and hepatic transplant patients. Clin Chem 43: 1989–1991
Acknowledgement
The authors thank Monique Mullens for her assistance with the pharmacokinetic part of the study.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
van Duijnhoven, E.M., Boots, J.M.M., Christiaans, M.H.L. et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 16, 721–725 (2003). https://doi.org/10.1007/s00147-003-0615-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00147-003-0615-1